PDX1 and pancreatic insulinoma: The results are in accordance with the aforementioned findings by Yang et al. [67] and with the established indolence of insulinomas (mainly PDX1+), although the group with a more favorable clinical outcome has been expanded to encompass all PDX1+ cases, irrespective of functional status.